Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Intangibles (2018 - 2023)

Historic Intangibles for Sangamo Therapeutics (SGMO) over the last 8 years, with Q1 2023 value amounting to $51.6 million.

  • Sangamo Therapeutics' Intangibles fell 213.37% to $51.6 million in Q1 2023 from the same period last year, while for Mar 2023 it was $51.6 million, marking a year-over-year decrease of 213.37%. This contributed to the annual value of $50.7 million for FY2022, which is 563.8% down from last year.
  • According to the latest figures from Q1 2023, Sangamo Therapeutics' Intangibles is $51.6 million, which was down 213.37% from $50.7 million recorded in Q4 2022.
  • Over the past 5 years, Sangamo Therapeutics' Intangibles peaked at $58.1 million during Q4 2020, and registered a low of $46.4 million during Q3 2022.
  • Its 5-year average for Intangibles is $53.1 million, with a median of $53.2 million in 2019.
  • Per our database at Business Quant, Sangamo Therapeutics' Intangibles skyrocketed by 935.36% in 2020 and then tumbled by 1545.48% in 2022.
  • Quarter analysis of 5 years shows Sangamo Therapeutics' Intangibles stood at $53.2 million in 2019, then rose by 9.35% to $58.1 million in 2020, then decreased by 7.51% to $53.8 million in 2021, then decreased by 5.64% to $50.7 million in 2022, then grew by 1.63% to $51.6 million in 2023.
  • Its Intangibles was $51.6 million in Q1 2023, compared to $50.7 million in Q4 2022 and $46.4 million in Q3 2022.